1h Free Analyst Time
The Diabetic Neuropathy Market size was estimated at USD 3.50 billion in 2023, USD 3.72 billion in 2024, and is expected to grow at a CAGR of 6.37% to reach USD 5.40 billion by 2030 . Speak directly to the analyst to clarify any post sales queries you may have.
Diabetic neuropathy is a medical condition that damages the nerve and occurs in patients who have diabetes. High blood sugar (glucose) can damage nerves throughout the body, and diabetic neuropathy most frequently impacts nerves in the legs and feet. The increasing need for effective treatment for diabetic neuropathy, diagnosis of diabetes, and several government initiatives are the major driving factors for the growth of the diabetic neuropathy market. In addition, the growing awareness about diabetic neuropathy, increased healthcare spending, and a rise in pharmaceutical R&D spending contribute to developing novel drugs and systems for treating diabetic neuropathy. However, the high cost of medications used to treat diabetic neuropathy and the availability of alternative therapies may limit their use by diabetic patients. Production of advanced drug delivery systems and rising research in diabetic neuropathy are leading to the development of a breakthrough system for the effective management of diabetic neuropathy conditions, accelerating their use by patients in the forecast period.
Regional Insights
The Americas has a significant market in diabetic neuropathy due to the presence of a rising number of diabetic patients and increasing awareness related to diabetes disorders. Approvals from the FDA for new product development and ongoing research activities for developing novel and effective drugs are major growth factors in the Americas region. The Asia-Pacific region represents a growing landscape for the global diabetic neuropathy market due to increasing R&D activities in drug development. Several start-ups focusing on developing diabetic neuropathy treatments in the APAC region have contributed to the market growth. Government support to raise awareness regarding diabetes management and increased research and development of novel drugs and systems for relieving pain and efficient management of diabetic neuropathy conditions are creating the immense potential for the deployment of diabetic neuropathy drugs and systems in the EMEA region. Additionally, the introduction of innovative treatments and drug delivery systems is expected to contribute to the growth of the diabetic neuropathy market worldwide.Treatment Type: Wide use of drugs for pharmacological treatment in diabetic neuropathy for alleviating pain and stabilizing nerve function
Drugs are used in the pharmacological treatment of diabetic neuropathy for alleviating pain and stabilizing nerve function. Pregabalin (Lyrica) and gabapentin (Neurontin) are popular anticonvulsant drugs for managing nerve pain in diabetic neuropathy patients. Among opioids, Tramadol (Ultram) is a centrally-acting opioid analgesic prescribed for moderate to severe pain associated with diabetic neuropathy. Physiotherapy, also known as physical therapy, is a non-pharmacological treatment that can help diabetic neuropathy patients improve their functional abilities and alleviate pain. Regular exercise and strengthening programs supervised by a certified physiotherapist can help improve muscle strength, balance, and endurance in diabetic neuropathy patients. Physiotherapy is often preferred to avoid side effects or contraindications.Disorder Type: Preference for diabetic neuropathy due to increasing prevalence of peripheral neuropathy
Autonomic neuropathy affects the autonomic nervous system, which controls the involuntary functions of internal organs. Patients with this condition experience irregular heartbeat, urinary problems, digestive issues, and sexual dysfunction. Based on individual needs, treatments include medications to regulate blood pressure and heart rate, drugs for gastrointestinal motility, and medications to treat erectile dysfunction. Focal neuropathy is a disorder that affects a single nerve or group of nerves, causing severe pain or weakness localized in specific body parts such as hands, feet, or torso. The treatment addresses the underlying cause, such as compression or entrapment, including splinting or bracing for carpal tunnel syndrome or surgical intervention for severe cases. Peripheral neuropathy is the most common type, affecting the nerves of arms, hands, legs, and feet. Symptoms include numbness, tingling, pain, and weakness. Treatment preferences depend on individual needs, including over-the-counter pain relievers and prescription medications. Proximal neuropathy primarily affects the hip, buttock, or thigh muscles with symptoms such as severe pain and muscle weakness.Distribution channel: Emergence of online pharmacies as a convenient distribution channel for medications prescribed for diabetic neuropathy management
Patients with diabetic neuropathy prefer clinics for convenience, affordability, and accessibility as they provide specialized care through a team of experts, including endocrinologists, podiatrists, and diabetes educators. Hospitals serve as comprehensive care providers for diabetic neuropathy patients requiring more extensive treatment or emergency interventions due to severe complications such as infections or ulcers. They offer access to equipment and multidisciplinary teams with expertise in treating complex cases. Online pharmacies have emerged as a convenient distribution channel for medications prescribed for diabetic neuropathy management, such as pain relievers, anti-seizure medications, and antidepressants. Patients prefer online pharmacies due to their ease of use, discreet delivery options, and competitive pricing compared to retail pharmacies. Retail pharmacies are popular for obtaining medications and over-the-counter supplements to manage diabetic neuropathy. They offer the advantage of face-to-face interaction with pharmacists who can provide personalized advice, medication management support, and access to a wide range of products.Market Dynamics
The market dynamics represent an ever-changing landscape of the Diabetic Neuropathy Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.Market Disruption Analysis
The market disruption analysis delves into the core elements associated with market-influencing changes, including breakthrough technological advancements that introduce novel features, integration capabilities, regulatory shifts that could drive or restrain market growth, and the emergence of innovative market players challenging traditional paradigms. This analysis facilitates a competitive advantage by preparing players in the Diabetic Neuropathy Market to pre-emptively adapt to these market-influencing changes, enhances risk management by early identification of threats, informs calculated investment decisions, and drives innovation toward areas with the highest demand in the Diabetic Neuropathy Market.Porter’s Five Forces Analysis
The porter's five forces analysis offers a simple and powerful tool for understanding, identifying, and analyzing the position, situation, and power of the businesses in the Diabetic Neuropathy Market. This model is helpful for companies to understand the strength of their current competitive position and the position they are considering repositioning into. With a clear understanding of where power lies, businesses can take advantage of a situation of strength, improve weaknesses, and avoid taking wrong steps. The tool identifies whether new products, services, or companies have the potential to be profitable. In addition, it can be very informative when used to understand the balance of power in exceptional use cases.Value Chain & Critical Path Analysis
The value chain of the Diabetic Neuropathy Market encompasses all intermediate value addition activities, including raw materials used, product inception, and final delivery, aiding in identifying competitive advantages and improvement areas. Critical path analysis of the <> market identifies task sequences crucial for timely project completion, aiding resource allocation and bottleneck identification. Value chain and critical path analysis methods optimize efficiency, improve quality, enhance competitiveness, and increase profitability. Value chain analysis targets production inefficiencies, and critical path analysis ensures project timeliness. These analyses facilitate businesses in making informed decisions, responding to market demands swiftly, and achieving sustainable growth by optimizing operations and maximizing resource utilization.Pricing Analysis
The pricing analysis comprehensively evaluates how a product or service is priced within the Diabetic Neuropathy Market. This evaluation encompasses various factors that impact the price of a product, including production costs, competition, demand, customer value perception, and changing margins. An essential aspect of this analysis is understanding price elasticity, which measures how sensitive the market for a product is to its price change. It provides insight into competitive pricing strategies, enabling businesses to position their products advantageously in the Diabetic Neuropathy Market.Technology Analysis
The technology analysis involves evaluating the current and emerging technologies relevant to a specific industry or market. This analysis includes breakthrough trends across the value chain that directly define the future course of long-term profitability and overall advancement in the Diabetic Neuropathy Market.Patent Analysis
The patent analysis involves evaluating patent filing trends, assessing patent ownership, analyzing the legal status and compliance, and collecting competitive intelligence from patents within the Diabetic Neuropathy Market and its parent industry. Analyzing the ownership of patents, assessing their legal status, and interpreting the patents to gather insights into competitors' technology strategies assist businesses in strategizing and optimizing product positioning and investment decisions.Trade Analysis
The trade analysis of the Diabetic Neuropathy Market explores the complex interplay of import and export activities, emphasizing the critical role played by key trading nations. This analysis identifies geographical discrepancies in trade flows, offering a deep insight into regional disparities to identify geographic areas suitable for market expansion. A detailed analysis of the regulatory landscape focuses on tariffs, taxes, and customs procedures that significantly determine international trade flows. This analysis is crucial for understanding the overarching legal framework that businesses must navigate.Regulatory Framework Analysis
The regulatory framework analysis for the Diabetic Neuropathy Market is essential for ensuring legal compliance, managing risks, shaping business strategies, fostering innovation, protecting consumers, accessing markets, maintaining reputation, and managing stakeholder relations. Regulatory frameworks shape business strategies and expansion initiatives, guiding informed decision-making processes. Furthermore, this analysis uncovers avenues for innovation within existing regulations or by advocating for regulatory changes to foster innovation.FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Diabetic Neuropathy Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Diabetic Neuropathy Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.Recent Developments
Neuralace Medical Completes Enrollment of Painful Diabetic Neuropathy Label Expansion Study (AT-PDN) Paving the Way for FDA Clearance and a Breakthrough, Non-invasive Treatment for Diabetes related Neuropathic Pain
NeuraLace Medical, Inc. announced the completion of enrollment in the AT-PDN study, which involved randomizing 70 patients into treatment and sham groups. This development represents a potential breakthrough in the treatment of PDN, with the potential to benefit millions of patients.GBP 1.4 million Awarded to Create early test for Diabetic Peripheral Neuropathy
Scientists from the University of Liverpool and Manchester Metropolitan University have received funding of GBP 1.4 million to develop an early test for Diabetic Peripheral Neuropathy (DPN). The project involves collaboration between university investigators and partners such as Aintree University Hospital and Weill Cornell Medicine, funded by the Engineering & Physical Sciences Research Council (EPSRC) for over GBP 1 million.Horizon Therapeutics PLC announced FDA approval of an update to the indication language for TEPEZZA (teprotumumab-trbw) to specify its use in thyroid eye disease (TED) patients regardless of disease activity or duration
Horizon Therapeutics PLC, a biopharmaceutical company focused on creating innovative medicines to enable people to live better lives, received an update from the United States Food and Drug Administration (FDA) regarding the approval of their drug, Tepezza. This drug has already been approved for treating thyroid eye disease and is now considered for treating diabetic neuropathy as well.Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Diabetic Neuropathy Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.Key Company Profiles
The report delves into recent significant developments in the Diabetic Neuropathy Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AdventHealth, Alkem Labs, Astellas Pharma Inc., AstraZeneca PLC, Bauerfeind AG, Bayer AG, Boehringer Ingelheim International GmbH, Boston Scientific Corporation, Collegium Pharmaceutical, Inc., Daiichi Sankyo Company, Limited, Dr. Reddy’s Laboratories Ltd., Eli Lilly and Company, Glenmark Pharmaceuticals Limited, Grünenthal GmbH, Harmonium Pharma s.r.l., Lupin Limited, Medtronic PLC, Merck KGaA, NeuroMetrix, Inc., Nevro Corp., Novartis AG, Novo Nordisk A/S, Pfizer Inc., Praetego, LLC, Regenacy Pharmaceuticals, Inc., Sanofi S.A., Stem Cell Care India, Teva Pharmaceutical Industries Ltd., The Procter & Gamble Company, Trevena, Inc., Vertex Pharmaceuticals Incorporated, Viatris Inc., and Winsantor, Inc..Market Segmentation & Coverage
This research report categorizes the Diabetic Neuropathy Market to forecast the revenues and analyze trends in each of the following sub-markets:- Treatment Type
- Drugs
- Analgesics
- Non-Steroidal Anti-Inflammatory Drugs
- Opioids
- Topical
- Anticonvulsants
- Gabapentin
- Pregabalin
- Topiramate
- Antidepressant
- Serotonin & Norepinephrine Reuptake Inhibitors
- SSRIs
- TCAs
- Analgesics
- Physiotherapy
- Drugs
- Disorder Type
- Autonomic Neuropathy
- Focal Neuropathy
- Peripheral Neuropathy
- Proximal Neuropathy
- Distribution channel
- Clinics
- Hospitals
- Online Pharmacy
- Retail Pharmacy
- Region
- Americas
- Argentina
- Brazil
- Canada
- Mexico
- United States
- California
- Florida
- Illinois
- New York
- Ohio
- Pennsylvania
- Texas
- Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
- Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom
- Americas
This research report offers invaluable insights into various crucial aspects of the Diabetic Neuropathy Market:
- Market Penetration: This section thoroughly overviews the current market landscape, incorporating detailed data from key industry players.
- Market Development: The report examines potential growth prospects in emerging markets and assesses expansion opportunities in mature segments.
- Market Diversification: This includes detailed information on recent product launches, untapped geographic regions, recent industry developments, and strategic investments.
- Competitive Assessment & Intelligence: An in-depth analysis of the competitive landscape is conducted, covering market share, strategic approaches, product range, certifications, regulatory approvals, patent analysis, technology developments, and advancements in the manufacturing capabilities of leading market players.
- Product Development & Innovation: This section offers insights into upcoming technologies, research and development efforts, and notable advancements in product innovation.
Additionally, the report addresses key questions to assist stakeholders in making informed decisions:
- What is the current market size and projected growth?
- Which products, segments, applications, and regions offer promising investment opportunities?
- What are the prevailing technology trends and regulatory frameworks?
- What is the market share and positioning of the leading vendors?
- What revenue sources and strategic opportunities do vendors in the market consider when deciding to enter or exit?
With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.
This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.
Table of Contents
1. Preface
2. Research Methodology
5. Market Insights
6. Diabetic Neuropathy Market, by Treatment Type
7. Diabetic Neuropathy Market, by Disorder Type
8. Diabetic Neuropathy Market, by Distribution channel
9. Americas Diabetic Neuropathy Market
10. Asia-Pacific Diabetic Neuropathy Market
11. Europe, Middle East & Africa Diabetic Neuropathy Market
12. Competitive Landscape
13. Competitive Portfolio
List of Figures
List of Tables
Companies Mentioned
- Abbott Laboratories
- AdventHealth
- Alkem Labs
- Astellas Pharma Inc.
- AstraZeneca PLC
- Bauerfeind AG
- Bayer AG
- Boehringer Ingelheim International GmbH
- Boston Scientific Corporation
- Collegium Pharmaceutical, Inc.
- Daiichi Sankyo Company, Limited
- Dr. Reddy’s Laboratories Ltd.
- Eli Lilly and Company
- Glenmark Pharmaceuticals Limited
- Grünenthal GmbH
- Harmonium Pharma s.r.l.
- Lupin Limited
- Medtronic PLC
- Merck KGaA
- NeuroMetrix, Inc.
- Nevro Corp.
- Novartis AG
- Novo Nordisk A/S
- Pfizer Inc.
- Praetego, LLC
- Regenacy Pharmaceuticals, Inc.
- Sanofi S.A.
- Stem Cell Care India
- Teva Pharmaceutical Industries Ltd.
- The Procter & Gamble Company
- Trevena, Inc.
- Vertex Pharmaceuticals Incorporated
- Viatris Inc.
- Winsantor, Inc.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 192 |
| Published | May 2024 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 3.72 Billion |
| Forecasted Market Value ( USD | $ 5.4 Billion |
| Compound Annual Growth Rate | 6.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 34 |
